As BCR-ABL P210 plays an important role in the prognosis and follow-up of TKI-treated CML patients, investigating whether COVID-19 could cause dynamic changes in BCR-ABL P210 and further influence the effect of TKI therapy is highly important. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.